



## **Colorcon, Inc. Launches New Starch Based Tableting Excipient Specifically for Direct Compression**

***STARTAB™ ensures functionality and stability while reducing formulation complexity***

Harleysville, Pennsylvania, USA, 14 May 2019, Colorcon Inc. announces an exciting new starch tableting excipient - STARTAB™ - designed specifically for the direct compression process.

In recent years, formulation scientists have become increasingly interested in direct compression (DC) tablet manufacturing processes. In response to this market trend, Colorcon has developed STARTAB™, Directly Compressible Starch. This represents a breakthrough for the DC process, where StarTab's unique particle size and shape provides excellent flow and superior compressibility on high-speed compression machines; enabling formulation scientists to simplify tablet formulation and manufacturing. StarTab also plays an important role in enhancing the stability of moisture sensitive active pharmaceutical ingredients.

Dr. Ali Rajabi-Siahboomi, Chief Scientific Officer at Colorcon explains that: "through extensive market and scientific research using particle engineering, we designed StarTab to be used as a single ingredient for the direct compression process. As StarTab uses material that is accepted by regulatory bodies across the world, there are no barriers to adoption of the product."

Jayesh Parmar, General Manager, Colorcon says: "the launch of this latest innovation meets the needs of the pharmaceutical industry for direct compression and is an advanced addition complementing the portfolio of solutions we provide through our starch product line."

This latest launch demonstrates Colorcon's continued leadership in bringing to market specialty excipients, as well as film coating systems, with improved convenience marked by speed and efficiency, cost savings and dependable performance.

### **Company Information**

Colorcon is a world leader in the development, supply and technical support of specialty ingredients; formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our extensive application data and value-added services to support all phases of solid oral dose design, development and



manufacture. Our focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply from multiple locations. Colorcon has 11 manufacturing facilities, 21 technical service laboratories globally and more than 1200 employees exclusively dedicated to its customer base.

For more information, visit [www.colorcon.com](http://www.colorcon.com)

COLORCON COMMUNICATIONS CONTACT:

Deborah J. Taylor

Director - Global Market Communications

Phone: +44-1322-627234

[dtaylor@colorcon.com](mailto:dtaylor@colorcon.com)